| Company Name | Novartis (Taiwan) Co., Ltd |
|---|---|
| Protocol Number | CENA713DTW05 |
| Title of Study | A 48-week, observational, longitudinal multicenter study on the effectiveness of 9.5 mg/24 h (10 cm2)Exelon in patients with mild to moderate dementia of the Alzheimer's type |
| Primary Objective | The primary objective of the study is to evaluate the effectiveness of rivastigmine patch in the management of the various cognitive symptoms in patients with AD in a real-world clinical setting |
| Number of Sites | 7 |
| Period of Study | From：April 1, 2016 to：December 31, 2018 |
| Number of Patients | 300人 |
| IRB Approval Date | March 8, 2016 |
| Publication Plan / Date | December, 2019 |
